Tesamorelin Dosing Protocol: GHRH Analog Research
Also known as: Egrifta, Trans-3-Hexenoyl-GHRH (1-44), Visceral Fat GHRH
Studied in human Phase 3 clinical trials — not medical advice. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg) SubQ once daily; research protocols evaluate 1–2 mg daily.
Once daily SubQ (typically before bed, ≥90 min after food)
FDA approval context: daily use. Research protocols commonly run 8–16 weeks followed by a 4-week washout.
SubQ injection (abdomen)
Phase 3 human RCTs & FDA-approved formulation (Egrifta)
~8–11 min (FDA labels: 8 min for Egrifta SV, 11 min for Egrifta WR, healthy subjects)
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 10 doses in the vial at the low end (5 doses at the high end).
Save Tesamorelin to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
Tesamorelin supplier & $/mg comparison.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a Growth Hormone Secretagogue?
A compound that stimulates your pituitary gland to release more of its own growth hormone (GH). Unlike synthetic GH injection, secretagogues trigger natural pulsatile GH release. Examples: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin. MK-677 (Ibutamoren) is technically not a peptide but acts as an oral GH secretagogue.
Tesamorelin is the same active compound as Egrifta, Egrifta SV (Theratechnologies). FDA approved for: HIV-associated lipodystrophy.
Bottom Line Up Front
Tesamorelin is an FDA-approved GHRH analog for HIV-associated lipodystrophy. It reduces visceral adipose tissue (VAT) in HIV patients. The only FDA-approved GHRH analog for a specific indication.
HIV-associated lipodystrophy, visceral fat reduction
General weight loss in healthy individuals
Egrifta (Theratechnologies)
22 (22 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Tesamorelin is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates endogenous growth hormone production. It is FDA-approved for HIV-associated lipodystrophy and has been studied for reducing visceral adipose tissue.
Mechanisms of Action
- Stimulates pituitary release of growth hormone
- Increases IGF-1 levels
- Reduces visceral adipose tissue
- Preserves subcutaneous fat
- Improves lipid profiles
Research Protocols
GH / IGF-1 & Glycemic Sensitivity Biomarker Panel (Tesamorelin)
Growth hormone secretagogues and somatomedin analogs directly elevate hepatic IGF-1 and can shift fasting insulin sensitivity via GH counter-regulatory signaling.
Serum IGF-1 (LC/MS) + Z-Score
Day 0 + Wk 6–8Why track at baseline: Establishes baseline somatotropic output before pituitary or local IGF-1R stimulation.
Week 6–8 check: Confirm physiological upper-quartile elevation (typically +30% to +80% above baseline) without supraphysiological overshoot (>300 ng/mL).
Fasting Insulin & HOMA-IR
Day 0 + Wk 6–8Why track at baseline: Pituitary GH pulses promote free fatty acid mobilization, which can transiently reduce peripheral insulin sensitivity.
Week 6–8 check: Keep Fasting Insulin <6–8 uIU/mL; if elevated, enforce strict 2–3 hr pre-bed fasting before GH secretagogue administration.
HbA1c & Fasting Plasma Glucose
Day 0 + Wk 6–8Why track at baseline: Screens for subclinical prediabetes prior to growth-factor or secretagogue exposure.
Week 6–8 check: Verify stable 90-day glycemic control (HbA1c <5.4% optimal) at Week 6–8.
hs-CRP, Prolactin & CMP
Day 0 + Wk 6–8Why track at baseline: Checks systemic inflammation, pituitary selectivity (no off-target prolactin/cortisol rise), and hepatic/renal clearance.
Week 6–8 check: Confirm Ipamorelin/CJC/Tesamorelin selectivity with unchanged Prolactin and normal liver transaminases.
Related Studies
Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.
Limitations: No placebo control reported. Review article — no new primary data.
BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability.
Limitations: No placebo control reported. Review article — no new primary data.
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
Human StudySeventy-three participants were randomized 3:2 to tesamorelin or SOC (2 mg subcutaneously daily). The primary outcome was the change in neurocognitive performance at 6 months, with secondary outcomes including WC, mood, and daily functioning.
Limitations: Standard limitations apply. Check original paper for full discussion.
Among 38 participants on INSTI-based regimens at baseline, 15 individuals on tesamorelin and 16 individuals on placebo completed the 12-month study. Tesamorelin led to significant declines in visceral fat (median [interquartile range]: -25 [-93, -2] vs.
Limitations: Standard limitations apply. Check original paper for full discussion.
Approach to the Patient With Lipodystrophy.
Human StudyThrough improved recognition of the lipodystrophy disorders, patients (and their affected family members) can be appropriately screened for cardiometabolic, noncardiometabolic, and syndromic abnormalities and undergo treatment with targeted interventions. Notably, insights gained through the study of this rare and extreme phenotype can inform our knowledge of more common disorders of adipose tissue overload, including generalized obesity.
Limitations: No placebo control reported. Case study — cannot establish causation.
Participants (193 responders, 148 placebo) were 87% male and 83% white. Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P = 0.80) and SAT density (-94 HU tesamorelin, -95 HU placebo, P = 0.29).
Limitations: Standard limitations apply. Check original paper for full discussion.
Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score. Our findings inform our knowledge of the biology of pulsatile growth hormone action and provide a mechanistic basis for the observed clinical effects of tesamorelin on the liver.
Limitations: Standard limitations apply. Check original paper for full discussion.
CSF1, a regulator of monocyte recruitment and activation, may serve as an innovative therapeutic target for NAFLD in HIV. Clinical Trials Registry Number: NCT02196831.
Limitations: Standard limitations apply. Check original paper for full discussion.
61 patients were enrolled between Aug 20, 2015, and Jan 16, 2019, of whom 30 received tesamorelin and 30 received placebo. Patients receiving tesamorelin had a greater reduction of HFF than did patients receiving placebo, with an absolute effect size of -4·1% (95% CI -7·6 to -0·7, p=0·018), corresponding to a -37% (95% CI -67 to -7, p=0·016) relative reduction from baseline.
Limitations: Standard limitations apply. Check original paper for full discussion.
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.
Human StudyAt baseline, serum log10 FGF21 was significantly associated with log10 liver fat (r=0.32, p=0.03). Log10 FGF21 tended to decrease in the tesamorelin group compared to placebo (p=0.06).
Limitations: Standard limitations apply. Check original paper for full discussion.
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.
Human StudyAt baseline, VAT was positively associated with ALT (P = 0.01). In study participants assigned to tesamorelin with baseline ALT or AST more than 30 U/l, VAT responders experienced greater reductions in ALT (-8.9 ± 22.6 vs.
Limitations: Standard limitations apply. Check original paper for full discussion.
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
Human StudyPlasma clearance and its interindividual variability [% coefficient of variation (CV)] was estimated to be 1,060 L/h (33.6 %). Volume of distribution was calculated to be 200 L (17.7 %).
Limitations: No placebo control reported.
Treatment of dyslipidemia in HIV.
Human StudyEffective therapeutic strategies can be challenging due to an increase risk of drug interactions and other comorbidities. Understanding the underlying pathophysiology and the principles of pharmacological and non-pharmacological therapeutic interventions can be of value in the appropriate management of dyslipidemia in the HIV-infected patient.
Limitations: No placebo control reported. Review article — no new primary data.
arthralgia, headache and peripheral oedema). Although long-term clinical experience is needed to further assess the benefits and risks of therapy, current evidence suggests that tesamorelin may be useful for reducing visceral adiposity in patients with HIV-associated lipodystrophy, thereby potentially improving self image.
Limitations: No placebo control reported. Review article — no new primary data.
arthralgia, headache and peripheral edema). Although long-term clinical experience is needed to further assess the benefits and risks of therapy, current evidence suggests that tesamorelin may be useful for reducing visceral adiposity in patients with HIV-associated lipodystrophy, thereby potentially improving self image.
Limitations: No placebo control reported. Review article — no new primary data.
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
Human StudyTesamorelin is effective in improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26-52 weeks of treatment. Potential limitations for its use include high cost and lack of long-term safety and adherence data.
Limitations: No placebo control reported. Review article — no new primary data.
How to diagnose a lipodystrophy syndrome.
Human StudyIn addition to the medical management of metabolic syndrome and the sometimes surgical treatment of lipodystrophy, recombinant leptin provides hope for genetically determined lipodystrophy syndromes, whereas modifications in antiretroviral treatment and tesamorelin, a GHRH analog, is effective in the metabolic syndrome of HIV patients. Other therapeutic options will undoubtedly be developed, dependent on pathophysiological advances, which today tend to classify genetically determined lipodystrophy as being related to laminopathy or to lipid droplet disorders.
Limitations: No placebo control reported. Review article — no new primary data.
Compared with tesamorelin nonresponders, responders experienced greater mean (±SD) reduction in triglyceride levels (26.
Limitations: Standard limitations apply. Check original paper for full discussion.
Tesamorelin.
Human StudyIn November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Limitations: No placebo control reported.
At baseline, VAT was significantly associated with PAI-1 antigen (ρ = 0.36, P < 0.001), tPA antigen (ρ = 0.29, P < 0.001), CRP (ρ = 0.18, P < 0.001), and adiponectin (ρ = -0.22, P < 0.001). Treatment with tesamorelin resulted in a significant decrease from baseline in tPA antigen (-2.2 ± 2.5 vs.
Limitations: Standard limitations apply. Check original paper for full discussion.
A multicenter, randomized, placebo-controlled, Phase III clinical trial suggested that tesamorelin might be a beneficial treatment strategy for HIV-related lipodystrophy with a good safety profile and a positive effect on reducing visceral fat. Other potential indications for tesamorelin appear less promising from the current data.
Limitations: Review article — no new primary data.
Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin.
Limitations: No placebo control reported. Review article — no new primary data.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •May increase risk of diabetes
- •Fluid retention possible
- •Carpal tunnel syndrome reported
- •Requires daily injections
Where to get Tesamorelin, baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Where to buy Tesamorelin: best verified price
Prices checked Nov 11, 2026 · sorted by $/mg · RUO
- 1. Ascension Peptides — $5.00/mg (5mg Lyophilized Vial, $25.00)
- 2. Polaris Peptides — $6.50/mg (10mg vial, $65.00)
- 3. Bulletproof BioLabs — $7.20/mg (10mg vial, $72.00)
Where is the cheapest place to buy Tesamorelin?
As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $5.00/mg (5mg Lyophilized Vial, $25.00 after the 50% new-customer partner-link discount). We compared 11 US suppliers with live, checked prices.
How much does Tesamorelin cost per mg?
Verified US domestic prices currently range from $5.00/mg to $14.00/mg depending on supplier and vial size. Larger vials usually lower the $/mg.
How are these prices verified?
Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.
Is Tesamorelin approved for human use?
Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.
All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More hormonal peptides
CJC-1295 (No DAC / Mod GRF 1-29)
CJC-1295 is a synthetic analog of growth hormone-releasing h...
Ipamorelin
Ipamorelin is a growth hormone secretagogue that selectively...
GHRP-2 (Pralmorelin)
GHRP-2 is a synthetic growth hormone-releasing peptide that ...
GHRP-6
GHRP-6 is a first-generation growth hormone-releasing peptid...
Hexarelin
Hexarelin is a synthetic growth hormone-releasing peptide (G...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.